Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry
The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field.
PALM BEACH, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - A report from Fortune Business Insights said that the global artificial intelligence in healthcare market size is projected to grow from USD 27.69 billion in 2024 to USD 490.96 billion by 2032, exhibiting a CAGR of 43.2% during the forecast period. The report added: “AI in healthcare market in the U.S. is experiencing rapid expansion, driven by the increasing adoption of AI-powered solutions for diagnostics, personalized treatment, and administrative automation. North America dominated the AI in the healthcare market with a market share of 44.93% in 2023. Artificial Intelligence in healthcare is used to analyze the medical data that helps doctors and medical providers deliver accurate diagnoses and treatments to their patients. AI in healthcare assists doctors, nurses, and other healthcare workers to enhance their productivity. This advancement helps patients in treatment and improves their quality of life. Also, according to an article published by GE Healthcare, it is found that healthcare professionals are already using AI to improve data analysis, which has enabled them to diagnose their patients in a better way with proper predictions for the treatment and decrease the time spent by the medical staff on administrative functioning.” Active companies active in the healthcare markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQTEM), Teladoc Health NYSE: TDOCNYSETDOC)(NASDAQ: ACONNASDAQACON, Medtronic plc (NYSE:MDTNYSE).
On Thursday, March 6, 2025 Ark Invest made significant trades in Tempus AI and GitLab, increasing its tech and AI exposure after their earnings reports, while also adjusting positions in other stocks.
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.
Tempus AI Inc (NASDAQTEM) shares are trading lower Tuesday after the company reported mixed fourth-quarter financial results. JPMorgan also downgraded the stock following the print.
The stock market experienced a correction on Monday, with the Nasdaq Composite sliding over 200 points. Meanwhile, the Dow inched up 0.08% to 43,461.21, while the Nasdaq dropped 1.2% to 19,286.92. The S&P 500 also declined, slipping 0.5% to 5,983.25. These are the top stocks that gained the attention of retail traders and investors throughout the day:
Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024.
Tempus shares may be moving higher ahead of its 2024 fiscal-year fourth-quarter earnings report, which is scheduled to be released after the market closes.
Tempus AI (TEM) reports Q4 earnings Monday, expected loss of 20 cents/share, $203.12M in revenues. Stock up 98.80% YTD. Analysts see 13.5% upside with consensus rating of Buy and $59.60 price target.
Tempus AI, Inc. (NASDAQTEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on March 3-5, 2025 in Boston, MA.
Ares Management Corporation (NYSEARES) (“Ares”), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI, Inc. NASDAQ: TEMNASDAQTEM)
